Quark Pharmaceuticals announces study on use of siRNA

Fremont, Calif. (ANTARA News/PRNewswire-AsiaNet) - Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008. The paper, entitled RNAi-Mediated Silencing of Nuclear Factor Erythroid-2Related Factor 2 Gene Expression in NonSmall Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy, reports on research performed in collaboration with Professor Shyam Biswal of the Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University. The results provide a basis for a potential new drug... [read full story]